Announced
Completed
Synopsis
Pfizer, a pharmaceutical and biotechnology corporation, completed the acquisition of Arena Pharmaceuticals, a clinical stage company developing potential therapies for the treatment of several immuno-inflammatory diseases, for $6.7bn. “We are excited to add the impressive experience and pipeline of Arena Pharmaceuticals to Pfizer’s Inflammation and Immunology therapeutic area, helping us further our purpose of developing breakthroughs to change the lives of those with immuno-inflammatory diseases. In particular, we’re hopeful that we can accelerate clinical development of etrasimod successfully to have a positive impact on those living with these debilitating diseases,” Mike Gladstone, Pfizer Inflammation and Immunology Global President & General Manager.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.